Evidence map›Paper›PMID 41535448›Full record

ArticleBritish journal of cancer2026

Tumour immune contexture and immune evasion in sporadic and Lynch syndrome-associated microsatellite unstable colorectal cancers.

Samantha Martin, Hanna Elomaa, Juha P Väyrynen, Maarit Ahtiainen, Erkki-Ville Wirta, Jan Böhm, Toni T Seppälä, Ari Ristimäki, Kyösti Tahkola, Anne Mattila and 7 more

Abstract read
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Samantha MartinMedicum/Department of Medical and Clinical Genetics, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0009-0009-8673-7583
Hanna ElomaaResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Juha P VäyrynenTranslational Medicine Research Unit, University of Oulu, Medical Research Center Oulu, and Oulu University Hospital, Oulu, Finland.ORCID http://orcid.org/0000-0002-8683-2996
Maarit AhtiainenCentral Finland Biobank, Hospital Nova of Central Finland, Well Being Services County of Central Finland, Jyväskylä, Finland.
Erkki-Ville WirtaDepartment of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland.ORCID http://orcid.org/0000-0002-2255-6136
Jan BöhmDepartment of Pathology, Hospital Nova of Central Finland, Well Being Services County of Central Finland, Jyväskylä, Finland.
Toni T SeppäläApplied Tumor Genomics Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland.
Ari RistimäkiApplied Tumor Genomics Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland.
Kyösti TahkolaDepartment of Surgery, Wellbeing Services County of Central Finland, Hospital Nova of Central Finland, Jyväskylä, Finland.
Anne MattilaDepartment of Surgery, Wellbeing Services County of Central Finland, Hospital Nova of Central Finland, Jyväskylä, Finland.
Selja KoskensaloThe HUCH Gastrointestinal Clinic, Helsinki University Central Hospital, Helsinki, Finland.
Laura Renkonen-SinisaloApplied Tumor Genomics Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland.
Anna LepistöApplied Tumor Genomics Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland.
Jukka-Pekka MecklinDepartment of Education and Research, Hospital Nova of Central Finland, Well Being Services County of Central Finland, Jyväskylä, Finland.
Kimmo PalinMedicum/Department of Medical and Clinical Genetics, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-4621-6128
Kristiina RajamäkiMedicum/Department of Medical and Clinical Genetics, University of Helsinki, Helsinki, Finland.
Lauri A AaltonenMedicum/Department of Medical and Clinical Genetics, University of Helsinki, Helsinki, Finland. lauri.aaltonen@helsinki.fi.ORCID http://orcid.org/0000-0001-6839-4286

Funding

Academy of Finland (Suomen Akatemia) 338657Jane ja Aatos Erkon Säätiö (Jane and Aatos Erkko Foundation) 21002Sigrid Juséliuksen Säätiö (Sigrid Jusélius Foundation) 230002, 240002Sigrid Juséliuksen Säätiö (Sigrid Jusélius Foundation) 240194Syöpäsäätiö (Cancer Foundation Finland) 200071Syöpäsäätiö (Cancer Foundation Finland) 59-5619, 69-7354Syöpäsäätiö (Cancer Foundation Finland) 63-6409Wellcome Trust 220001
6 · The paper itself

Abstract

backgroundThe high mutational burden in microsatellite unstable colorectal cancers (MSI CRCs) results in high immunogenicity, yet response rates to immunotherapy vary, suggesting underlying heterogeneity of the tumour immune landscape. Here, our aims were (1) to characterise the immune cell infiltrate and immune evasion in MSI CRCs, (2) to correlate these with clinical and genomic features, and (3) to compare these between Lynch syndrome (LS) and sporadic MSI CRCs.

methodImmunohistochemistry was utilised to detect T cell and myeloid cell subsets. Whole-genome and RNA sequencing were utilised to analyse somatic variants, tumour clonality, neoantigen burden, antigen presentation, immune checkpoint expression, and consensus molecular subtypes.

resultsOur results revealed higher immune cell scores in LS tumours, depicting higher T cell infiltration, compared to sporadic tumours. Conversely, sporadic tumours displayed increased infiltration of protumorigenic M2-like macrophages and increased expression of immune checkpoints PDCD1LG2 and CD40LG. Across our MSI CRC cohort, high neoantigen burden was associated with low tumour clonality.

conclusionsOur findings reveal differences between sporadic MSI and LS tumours in T cell and myeloid immune cell landscapes, and in immune evasion. These differences may contribute to the variable immunotherapy responses among MSI CRC patients and are targetable by emerging therapeutic approaches.

Indexed as

Colorectal NeoplasmsColorectal Neoplasms, Hereditary NonpolyposisMicrosatellite InstabilityTumor EscapeFemaleHumansLymphocytes, Tumor-InfiltratingMaleMiddle AgedMutationProgrammed Cell Death 1 Ligand 2 ProteinT-LymphocytesPDCD1LG2 protein, humanProgrammed Cell Death 1 Ligand 2 Protein

Identifiers

PMID41535448
PMCPMC12996609

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.